 |
市場調查報告書
商品編碼
2080165
默克細胞癌（MCC）：新型療法、未滿足的需求和TPP洞察報告，2026年Merkel Cell Carcinoma (MCC) - Emerging Therapy, with Unmet Needs and TPP Insights Report - 2026 |
||||||
市場概覽
- 德國MCC市場預計將從2025年的1.8億美元成長到2035年的3.6億美元。
- 以下因素正在推動市場成長：
- 免疫查核點抑制劑的應用日益廣泛
- 繼續開發新的免疫腫瘤療法
- 未來的成長取決於能夠帶來持續療效並克服治療抗藥性的治療方法。
默克細胞癌 (MCC) 的新療法及對 TPP 的深入研究
Thelansis 的「默克爾細胞癌 (MCC)：新型療法、未滿足的需求和 TPP 洞察報告，2026」對該適應症的關鍵新興療法和主要藥物發現機會進行了全面分析，包括新興的競爭格局、未滿足的需求、目標產品概況 (TPP)、臨床試驗設計以及關鍵意見領袖 (KOL) 的見解。
默克細胞癌（MCC）概述
默克細胞癌 (MCC) 是一種高度侵襲性的神經內分泌皮膚惡性腫瘤，起源於機械感受器細胞，與梅克爾細胞脊髓灰質炎(MCPyV) 和累積紫外線損傷密切相關。它通常表現為快速生長、無痛的紫色結節，常見於日光暴露部位，特別多見於老年人和免疫力缺乏患者。診斷主要依據免疫組織化學觀察，其特徵性表現為核週細胞角質蛋白 20 (CK20) 和突觸素的點狀染色。根據 2026 年臨床指南，如果初次診斷是透過有限的穿刺切片檢查做出的，則應在治療前採集額外的腫瘤組織進行必要的分子水平基準檢測。對於局限性病變，治療方法包括廣泛的局部切除術、莫氏顯微外科手術，或對合格手術的患者採用低分割放射線治療單藥治療，通常聯合前哨淋巴結活體組織切片以檢測微小的局部轉移。對於進行性或轉移性默克爾細胞癌（MCC），免疫查核點抑制劑，包括Avelumab、Pembrolizumab和來替凡利單抗，是一線標準治療方案。如果患者對PD-1/PD-L1單藥治療產生抗藥性，則根據最新的治療流程，逐步過渡到Ipilimumab合併納武Nivolumab的聯合治療治療。此外，後續觀察也已從傳統的影像診斷發展到如今的成熟。目前，血清脊髓灰質炎抗體檢測和體液循環腫瘤DNA（ctDNA）檢測已被系統地納入常規的長期隨訪中，以便在出現肉眼可見的病灶之前，從分子水平上檢測出復發。
主要亮點
- 在德國，默克細胞癌 (MCC) 的診斷數量預計將從 2025 年的 315 例增加到 2035 年的 335 例。
- MCC 是一種罕見且高度侵襲性的神經內分泌皮膚癌，具有很高的復發和轉移風險。
- 儘管免疫療法取得了進展，但對於晚期或難治性疾病患者來說，預後仍然很差。
- 目前仍有大量未被滿足的治療需求，亟需能提高長期存活率和持續控制疾病的治療方法。
透過對醫生和關鍵意見領袖 (KOL) 的調查所獲得的見解：
- 透過對關鍵意見領袖 (KOL) 的訪談，我們獲得了更多見解，從而進一步完善了調查結果。
- 調查問卷將根據客戶的要求進行客製化。
交付成果格式：
- PowerPoint簡報
- MS Excel
主要問題
- 詳細的競爭格局趨勢
- 管道分析
- 符合新興療法條件的患者
- 大公司
- 主要作用機制
- 發布日期等的預測
- 臨床試驗現況分析
- 目標患者群
- 試驗終點
- 測試設計
- 受試者招募標準等。
- 未滿足的需求和機遇
- 目前主要療法的有效性
- 未滿足需求的關鍵領域
- 主要未滿足需求的市場規模估算
- 目標產品概況
- 特徵和級別
- 醫生開立的處方
- 預期患者佔有率
- 關鍵意見領袖對領先新興療法的見解
- 意識
- 預期用途/處理線
- 學位旨在解決重大未滿足的需求
- KOL評論
目標國家
- G8
- 美國
- EU5
- 法國
- 德國
- 義大利
- 西班牙
- 英國
- 日本
- 中國
大公司
- Merck Sharp &Dohme LLC
- Incyte Corporation
- Fujifilm Pharmaceuticals USA, Inc.
- Replimune, Inc.
- Phio Pharmaceuticals Inc.
- Sotio Biotech Inc.
- Kupando GmbH
- AstraZeneca
- Checkpoint Therapeutics, Inc.
- ImmunityBio, Inc.
- KaliVir Immunotherapeutics
- Neonc Technologies, Inc.
- SystImmune Inc.
- Medicenna Therapeutics, Inc.
- Sensei Biotherapeutics, Inc.
目錄
第1章：主要調查結果及分析師說明
- 主要趨勢：市場概況、SWOT分析、商業性利益與風險等。
第2章 競爭情勢
- 目前的治療方法
- 重點
- 診斷和治療過程/演算法
- 主要療法概述及關鍵意見領袖見解
- 新興療法
- 重點
- 診斷和治療過程/演算法
- 領先的新興療法—概述和關鍵意見領袖見解
第3章 產品屬性分析
- 重點
- 科學屬性
- 商業性屬性
- 產品定位
第4章：初步調查
- 目前治療狀態
- 主要治療方法與目標患者族群的比較
- 主要特點和優勢
- 未來治療環境
- 當前挑戰
- 未滿足的需求
- 新興療法
- 主要治療方法與目標患者族群的比較
- 主要特點和優勢
- 未來治療前景
- 未滿足的需求和關鍵意見領袖的期望
第5章：未滿足的需求和TPP分析
- 新興療法的主要未滿足需求和未來成就
- TPP分析與KOL預期
第6章 監理與報銷環境
第7章附錄
Merkel Cell Carcinoma (MCC) Emerging Therapy and TPP Insights
Thelansis's "Merkel Cell Carcinoma (MCC) Emerging Therapy, with Unmet Needs and TPP Insights Report - 2026" provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.
Merkel Cell Carcinoma (MCC) Overview
Merkel Cell Carcinoma (MCC) is an aggressive neuroendocrine skin malignancy arising from mechanoreceptor cells, heavily linked to the Merkel cell polyomavirus (MCPyV) and cumulative UV-induced damage. It typically manifests as a fast-growing, painless, violaceous nodule on sun-exposed sites in elderly or immunocompromised individuals. Diagnosis relies on immunohistochemical profiling showing characteristic dot-like perinuclear cytokeratin 20 (CK20) and synaptophysin staining. Under 2026 clinical guidelines, if initial diagnosis is made via limited core biopsy, capturing additional tumor tissue prior to treatment is mandatory to run necessary molecular baselines. Localized disease is treated with wide local excision, Mohs micrographic surgery, or single-modality hypofractionated radiation for inoperable candidates, paired with sentinel lymph node biopsy to detect microscopic regional spread. For advanced or metastatic MCC, immune checkpoint inhibitors-including avelumab, pembrolizumab, and retifanlimab-serve as the first-line standard. If a patient develops resistance to PD-1/PD-L1 monotherapy, advanced algorithms dictate escalating to dual-agent ipilimumab and nivolumab. Furthermore, surveillance has evolved significantly past conventional imaging alone; routine long-term follow-up now systematically integrates serological polyomavirus antibody tracking and circulating tumor DNA (ctDNA) liquid assays to detect molecular recurrence long before macroscopic lesions appear.
Key Highlights
- In Germany, diagnosed Merkel Cell Carcinoma (MCC) cases are projected to increase from 315 in 2025 to 335 by 2035.
- MCC is a rare and aggressive neuroendocrine skin cancer associated with a high risk of recurrence and metastasis.
- Despite advances in immunotherapy, patients with advanced or treatment-refractory disease continue to face poor clinical outcomes.
- Significant unmet need remains for therapies capable of improving long-term survival and durable disease control.
Market Overview
- The Germany MCC market is projected to grow from $180M in 2025 to $360M by 2035.
- Market growth is driven by:
- Increasing adoption of immune checkpoint inhibitors
- Ongoing development of novel immuno-oncology therapies
- Future growth will depend on therapies capable of delivering durable responses and overcoming treatment resistance.
Insights driven by surveys with physician / key opinion leaders:
- Survey findings are corroborated and enriched by insights from interviews with leading KOLs
- Survey is customized based on client requirements
Deliverables format:
- PowerPoint presentation
- MS Excel
Key business questions answered:
- Detailed emerging competitive landscape
- Pipeline analysis
- Target patients for emerging therapies
- Key companies
- Key mechanism of actions
- Launch date estimates, etc.
- Clinical trial landscape analysis
- Target patient segments
- Trial endpoints
- Trial design
- Recruitment criteria, etc.
- Unmet Needs and Opportunities
- Performance of key current therapies
- Top areas of unmet needs
- Opportunity sizing for key unmet needs
- Target Product Profiles
- Attributes and levels
- Physician likelihood of prescribing
- Expected patient shares
- KOL insights on key emerging therapies
- Level of awareness
- Expected use / line of therapy
- Extent to fulfil key unmet needs
- KOL quotes
Countries Covered
- G8
- United States
- EU5
- France
- Germany
- Italy
- Spain
- U.K.
- Japan
- China
Apart from the G8 Market, adding any additional country data to the dashboard will cost USD 1,750 per country
Companies Mentioned
- Merck Sharp & Dohme LLC
- Incyte Corporation
- Fujifilm Pharmaceuticals U.S.A., Inc.
- Replimune, Inc.
- Phio Pharmaceuticals Inc.
- Sotio Biotech Inc.
- Kupando GmbH
- AstraZeneca
- Checkpoint Therapeutics, Inc.
- ImmunityBio, Inc.
- KaliVir Immunotherapeutics
- Neonc Technologies, Inc.
- SystImmune Inc.
- Medicenna Therapeutics, Inc.
- Sensei Biotherapeutics, Inc.
Table of Contents
1. Key Findings and Analyst Commentary
- Key trends: market snapshots, SWOT analysis, commercial benefits and risk, etc.
2. Competitive Landscape
- Current therapies
- Key takeaways
- Dx and Tx journey/algorithm
- Key current therapies - profiles and KOL insights
- Emerging therapies
- Key takeaways
- Dx and Tx journey/algorithm
- Key emerging therapies - profiles and KOL insights
3. Product Attribute Analysis
- Key takeaways
- Scientific attributes
- Commercial attributes
- Product positioning
4. Primary Market Research
- Current treatment landscape
- Key therapies vs. focused patient segment
- Key attributes and benefits
- Futures treatment landscape
- Current challenges
- Unmet needs
- Emerging therapies
- Key therapies vs. focused patient segment
- Key attributes and benefits
- Futures treatment landscape
- Unmet needs and KOL expectations
5. Unmet Need and TPP Analysis
- Top unmet needs and future attainment by emerging therapies
- TPP analysis and KOL expectations
